Given the adverse contribution of RBP4 to the response of ischemic injury in mice and the phenotype observed in patients with Matthew-Wood syndrome, RBP4 rather than STRA6 might be a potential therapeutic approach for the treatment of MI. Here, STRA6 is linked to Matthew-Wood syndrome.